Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm
Protalix BioTherapeutics, Inc. (DE) (PLX)
NASDAQ:AMEX Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-irhome
Company Research
Source: Business Wire
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Protalix BioTherapeutics, Inc. (NYSE: PLX) (“Protalix”) on behalf of the company’s shareholders.Since May 2023, shares of Protalix common stock have declined in value from a trading price of approximately $3.25 per share to a trading price of below $1.25 per share, a decline of over 61% in value.The investigation seeks to determine whether Protalix and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties to the company’s investors.Protalix shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750 for additional information about this investigation and their legal rights and options. Alternatively, investors may submit their information to the firm by clicking on the following link (or by copying and pasting the link into your browser):https://kaskelalaw.com/case/protalix-biotherapeutic
Show less
Read more
Impact Snapshot
Event Time:
PLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLX alerts
High impacting Protalix BioTherapeutics, Inc. (DE) news events
Weekly update
A roundup of the hottest topics
PLX
News
- Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024PR Newswire
- Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024 [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024 [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024GlobeNewswire
- Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference [Yahoo! Finance]Yahoo! Finance
PLX
Earnings
- 8/14/24 - Miss
PLX
Sec Filings
- 10/25/24 - Form SC
- 10/25/24 - Form 8-K
- 9/24/24 - Form 4
- PLX's page on the SEC website